Product Images Simvastatin
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 13 images provide visual information about the product associated with Simvastatin NDC 71610-615 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Bottle Label 10 mg - 71610 0615 45
Aphena Pharma Solutions - TN - Aphena
Footnote for Table 3 - Footnote for Table 3
This text provides information on the results of chemical assays for CYP3Ad inhibitors such as ketoconazole, erythromycin, clarithromycin, HIV, protease inhibitors, and nefazodone. It also explains the meaning of simvastatin acid, and mentions that the effects of different amounts of grapefruit juice on simvastatin pharmacokinetics have not been studied thoroughly. The text describes the administration of grapefruit juice and simvastatin at different strengths and times, with simvastatin administered on the third day.*
Figure 9 - simvastatin 10
table2 - simvastatin 2
This is a table showing the adverse reactions reported by patients treated with Simvastatin compared to placebo. The table shows the percentage of patients that reported each reaction regardless of whether it was related to the medication or not. The reactions are grouped by body system, including body as a whole, cardiovascular, digestive, endocrine, musculoskeletal, nervous system/psychiatric, respiratory, skin/skin appendage, and urogenital system disorders. Some of the reactions that were reported more frequently in patients taking Simvastatin than in those taking placebo include edema/swelling, atrial fibrillation, constipation, diabetes mellitus, myalgia, and eczema.*
Structure - simvastatin 3
table 3 - simvastatin 4
table 4 - simvastatin 5
Figure 5 - simvastatin 6
This appears to be a table displaying characteristics, patient counts, and risk ratios of major vascular events and major coronary events. The table is comparing the effectiveness of Simvastatin versus a Placebo in reducing the risk of these events in patients with or without certain conditions such as peripheral vascular disease and coxibzovascular disease. The exact values for risk ratios are not available as they only provide confidence intervals.*
Figure 6 - simvastatin 7
Figure 7 - simvastatin 8
The description is: "The text is not-readable."*
Figure 8 - simvastatin 9
table 1 - table1
This text contains a table listing drug interactions that are associated with an increased risk of MyopathyRhabdomyolysis, along with prescribing recommendations for each interaction. It includes drugs like CYP3A4 inhibitors, HIV protease inhibitors, verapamil, diltiazem, amiodarone, and others with corresponding dosage recommendations or precautions. The text is readable and informative.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.